title: Clinical relevance of antibodies to cardiolipin in patients with chronic hepatitis C.
abstract: The significance of antibodies to cardiolipin (anti-CL) remains uncertain in patients with chronic hepatitis C (CH-C). The main purpose of this study was to elucidate the clinical characteristics of patients with CH-C seropositive for anti-CL. The prevalence of anti-CL and clinical parameters associated with anti-CL in those patients were examined. Six of the 45 (13%) patients with CH-C had anti-CL. However, none of these six CH-C patients fulfilled the criteria for antiphospholipid syndrome. Serum triglyceride and apolipoprotein B (ApoB) levels in CH-C patients with anti-CL were significantly higher than those in CH-C patients without anti-CL. Serum triglyceride levels positively correlated with serum ApoB levels. CH-C patients with anti-CL had significantly more progressive hepatic fibrosis than those without anti-CL. The degree of 8-hydroxy 2'-deoxyguanosine (8-OHdG) expression in the liver tissue was more severe in CH-C patients with anti-CL than in those without it. However, the emergence of anti-CL in CH-C patients was independent of insulin resistance, hepatic steatosis, and iron overload. These findings suggest that the emergence of anti-CL is associated with oxidative stress and that CH-C patients seropositive for anti-CL have clinical characteristics of hypertriglyceridemia, which derives from the facilitation of ApoB synthesis, and progressive hepatic fibrosis.
authors.affiliation: Department of Integrated Medicine, Kagawa University School of Medicine, Kagawa, Japan. thimoto@med.kagawa-u.ac.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Himoto
authors.forename: Hirohito
authors.initials: H
authors.lastname: Yoneyama
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Kurokohchi
authors.forename: Hirohito
authors.initials: H
authors.lastname: Mori
authors.forename: Michio
authors.initials: M
authors.lastname: Inukai
authors.forename: Hisashi
authors.initials: H
authors.lastname: Masugata
authors.forename: Fuminori
authors.initials: F
authors.lastname: Goda
authors.forename: Reiji
authors.initials: R
authors.lastname: Haba
authors.forename: Seishiro
authors.initials: S
authors.lastname: Watanabe
authors.forename: Shoich
authors.initials: S
authors.lastname: Senda
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Masaki
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism; D005234:Fatty Liver / Q000097:blood / Q000276:immunology / Q000378:metabolism; D005260:Female; D019694:Hepatitis B, Chronic / Q000097:blood / Q000276:immunology / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000276:immunology / Q000378:metabolism; D006651:Histocytochemistry; D006801:Humans; D008099:Liver / Q000737:chemistry / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D014280:Triglycerides / Q000097:blood
chemical_list: D017153:Antibodies, Anticardiolipin; D001055:Apolipoproteins B; D014280:Triglycerides; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine